黑色素瘤临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 3

NCI NCT05549297 / NCI-2023-00567

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

AI 简述一项III期试验，比较Tebentafusp与医生选择方案用于既往治疗晚期黑色素瘤。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Unresectable Melanoma
干预: 未列出
地点: United States
申办方: Immunocore Limited

正在招募 Phase 3

NCI NCT06265285 / NCI-2024-00637

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

AI 简述这是一项III期试验，比较Nivolumab在家与在诊所给药用于多种癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 3

NCI NCT06264180 / NCI-2024-04401

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

AI 简述这是一项III期试验，比较VO联合Nivolumab与医生选择的方案用于晚期黑色素瘤。

?

适用疾病: Stage IV Cutaneous (Skin) Melanoma；Stage IIIB Cutaneous (Skin) Melanoma；Stage IIIC Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Replimune, Inc.

正在招募 Phase 2, Phase 3

NCI NCT06624644 / NCI-2025-00600

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

AI 简述这是一项II/III期试验，研究LNS8801联合或不联合Pembrolizumab用于难治性黑色素瘤。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Unresectable Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Linnaeus Therapeutics, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT02821013

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

AI 简述这是一项III期试验，在澳大利亚和加拿大等地开展，比较间断与持续PD-1抑制剂治疗用于不可切除/转移性黑色素瘤。

?

适用疾病: Unresectable/Metastatic Melanoma
干预: Intermittent PD-1 inhibitor therapy，Continuous PD-1 inhibitor therapy
地点: Australia，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

AI 简述这是一项III期试验，比较标准免疫治疗与每3个月给药一次的方案用于多种癌症。

?

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT05522660

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

AI 简述这是一项III期试验，研究立体定向放射手术联合免疫检查点抑制剂用于黑色素瘤或非小细胞肺癌脑转移，在意大利、荷兰等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Melanoma
干预: Stereotactic radiosurgery，Immune checkpoint inhibitor
地点: Italy，Netherlands，Spain，Switzerland 等 1 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 3 生物制剂

ClinicalTrials.gov / NCI NCT05727904 / NCI-2023-08958

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

AI 简述这是一项III期试验，研究Lifileucel联合Pembrolizumab对比Pembrolizumab单药用于未经治疗的晚期黑色素瘤。

?

适用疾病: Metastatic Melanoma；Unresectable Melanoma；Melanoma
干预: Lifileucel plus Pembrolizumab，Pembrolizumab with Optional Crossover Period
地点: United States，Australia，Belgium，Canada 等 12 个
申办方: Iovance Biotherapeutics, Inc.

正在招募 Phase 3 器械药物

ClinicalTrials.gov / NCI NCT06007690 / NCI-2023-07465

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

AI 简述这是一项III期试验，评价Bel-sar对比安慰剂用于原发性不确定病变或小脉络膜黑色素瘤。

?

适用疾病: Choroidal Melanoma；Indeterminate Lesions；Uveal Melanoma
干预: Bel-sar，Suprachoroidal Microinjector，Infrared Laser，Sham Infrared Laser
地点: United States，Australia，Austria，Belgium 等 10 个
申办方: Aura Biosciences

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06246149

Adjuvant Tebentafusp in High Risk Ocular Melanoma

AI 简述这是一项III期试验，在美、比、法、德等国研究Tebentafusp辅助治疗高风险葡萄膜黑色素瘤。

?

适用疾病: Uveal Melanoma
干预: Tebentafusp
地点: United States，Belgium，France，Germany 等 5 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06246916 / NCI-2024-04722

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

AI 简述这是一项III期试验，在美、加研究fianlimab联合cemiplimab对比relatlimab联合nivolumab用于晚期黑色素瘤。

?

适用疾病: Melanoma；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: fianlimab，cemiplimab，relatlimab+nivolumab
地点: United States，Canada
申办方: Regeneron Pharmaceuticals

正在招募 Phase 3 手术/操作放疗

ClinicalTrials.gov NCT06500455

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

AI 简述这是一项III期试验，比较长疗程放疗与常规放疗用于脑转移瘤，在美国、加拿大等地开展。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Digestive System Carcinoma
干预: Computed Tomography，Fractionated Stereotactic Radiation Therapy，Magnetic Resonance Imaging，Stereotactic Radiosurgery
地点: United States，Canada，Hong Kong，Ireland
申办方: NRG Oncology

正在招募 Phase 3 器械药物

ClinicalTrials.gov NCT06519266

PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases

AI 简述这是一项III期试验，比较PHP联合IPI1/NIVO3与IPI3/NIVO1用于葡萄膜黑色素瘤肝转移。

?

适用疾病: Uveal Melanoma；Liver Metastases
干预: PHP，IPI1/NIVO3，IPI3/NIVO1
地点: Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 2, Phase 3 生物制剂

ClinicalTrials.gov / NCI NCT06581406 / NCI-2024-07892

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

AI 简述这是一项II/III期试验，研究RP2联合Nivolumab用于未接受免疫检查点抑制剂的转移性葡萄膜黑色素瘤。在美国、澳大利亚、英国等地开展。

?

适用疾病: Metastatic Uveal Melanoma；Stage IV Choroidal and Ciliary Body Melanoma；Unresectable Uveal Melanoma
干预: RP2，Ipilimumab，Nivolumab
地点: United States，Australia，United Kingdom
申办方: Replimune, Inc.

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT06697301 / NCI-2025-03074

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

AI 简述这是一项2/3期试验，研究EIK1001联合Pembrolizumab对比安慰剂联合Pembrolizumab用于晚期黑色素瘤。

?

适用疾病: Advanced Melanoma；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: EIK1001，Pembrolizumab (KEYTRUDA® )
地点: United States，Australia，Austria，Belgium 等 20 个
申办方: Eikon Therapeutics

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT06743126 / NCI-2025-00318

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

AI 简述这是一项III期试验，比较IMA203与研究者选择的治疗方案用于既往治疗过的不可切除或转移性皮肤黑色素瘤。

?

适用疾病: Melanoma, Cutaneous Malignant；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: IMA203，nivolumab plus relatlimab，lifileucel，nivolumab
地点: United States，Canada，France，Germany 等 2 个
申办方: Immatics US, Inc.

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT07015190 / NCI-2025-08784

Neoadjuvant Darovasertib in Primary Uveal Melanoma

AI 简述这是一项III期试验，研究Darovasertib新辅助治疗原发性葡萄膜黑色素瘤，在美、澳、奥、比等地开展。

?

适用疾病: Uveal Melanoma；Stage I Choroidal and Ciliary Body Melanoma；Stage II Choroidal and Ciliary Body Melanoma
干预: Darovasertib，Primary Local Therapy
地点: United States，Australia，Austria，Belgium 等 17 个
申办方: IDEAYA Biosciences

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07221734

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

AI 简述这是一项III期试验，比较MB11与Opdivo®用于晚期黑色素瘤。

?

适用疾病: Advanced (Unresectable or Metastatic) Melanoma
干预: MB11 (Proposed Nivolumab Biosimilar)，EU-Opdivo®，US- sourced Opdivo®
地点: Portugal，Ukraine
申办方: mAbxience Research S.L.

正在招募 Phase 1, Phase 2

NCI NCT02332668 / NCI-2015-00528

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

AI 简述这是一项I/II期试验，研究Pembrolizumab用于儿童晚期实体瘤或淋巴瘤，在美国、巴西、法国、德国等地开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 2

NCI NCT03467516 / NCI-2018-00881

Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Patients with Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究环磷酰胺、氟达拉滨、肿瘤浸润淋巴细胞和阿地白介素用于转移性葡萄膜黑色素瘤。

?

适用疾病: Metastatic Uveal Melanoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT04145622 / NCI-2020-03139

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

AI 简述这是一项I/II期试验，研究Ifinatamab Deruxtecan用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT04218617 / NCI-2020-05088

Single- or Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases

AI 简述这是一项II期试验，研究单次或两次脊柱立体定向放射外科用于脊柱转移瘤。

?

适用疾病: Stage IV Renal Cell Cancer；Metastatic Renal Cell Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04219254 / NCI-2020-05456

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BI-1206联合Pembrolizumab用于晚期实体瘤，包括肺癌和黑色素瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: BioInvent International AB

正在招募 Phase 2

NCI NCT04139902 / NCI-2020-05492

Dostarlimab Alone or in Combination with Cobolimab for the Treatment of Resectable Stage III or IV Melanoma

AI 简述这是一项II期试验，研究Dostarlimab单药或联合Cobolimab用于可切除的III或IV期黑色素瘤，在美国开展。

?

适用疾病: Stage IV Cutaneous (Skin) Melanoma；Stage IIIB Cutaneous (Skin) Melanoma；Stage IIIC Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2

NCI NCT04114136 / NCI-2020-11521

Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors

AI 简述这是一项II期试验，研究PD-1抑制剂联合二甲双胍、罗格列酮用于多种实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT04464759 / NCI-2021-00960

Nivolumab and Hydroxychloroquine or Nivolumab, Ipilimumab, and Hydroxychloroquine for the Treatment of Stage III-IV Melanoma

AI 简述这是一项I/II期试验，研究纳武单抗和羟氯喹或联合伊匹单抗用于III-IV期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 2

NCI NCT04493203 / NCI-2021-07527

Nivolumab plus Axitinib for the Treatment of Stage III or IV Melanoma

AI 简述这是一项II期试验，研究Nivolumab联合Axitinib用于III或IV期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2

NCI NCT05026983 / NCI-2021-08716

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

AI 简述这是一项II期试验，研究Binimetinib联合Encorafenib用于IV期皮肤黑色素瘤伴中枢神经系统转移。

?

适用疾病: Stage IV Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT04996823 / NCI-2021-08823

Axitinib and Ipilimumab for the Treatment of Advanced Melanoma

AI 简述这是一项II期试验，研究阿西替尼和伊匹木单抗用于晚期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage IIIC Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Urothelial Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 1, Phase 2

NCI NCT04688658 / NCI-2021-13070

Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma

AI 简述这是一项I/II期试验，研究Duvelisib联合Nivolumab用于不可切除的IIIB-IV期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage IIIB Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT05098132 / NCI-2022-00633

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

AI 简述这是一项I/II期试验，研究STK-012单药及联合其他药物用于晚期肺癌等实体瘤，在美国、格鲁吉亚、爱尔兰、西班牙等地开展。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Synthekine

正在招募 Phase 2

NCI NCT04633902 / NCI-2022-01376

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

AI 简述这是一项II期试验，研究Olaparib联合Pembrolizumab用于伴有同源重组突变的晚期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Refractory Melanoma
干预: 未列出
地点: United States
申办方: California Pacific Medical Center-Pacific Campus

正在招募 Phase 1, Phase 2

NCI NCT05144698 / NCI-2022-01928

RAPA-201 Therapy of Solid Tumors

AI 简述这是一项I/II期试验，研究RAPA-201用于多种实体瘤。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Rapa Therapeutics LLC

正在招募 Phase 2

NCI NCT05384496 / NCI-2022-04623

Nivolumab in Combination with Axitinib for the Treatment of Advanced or Unresectable Mucosal Melanoma

AI 简述这是一项II期试验，研究Nivolumab联合阿昔替尼用于晚期或不能切除的黏膜黑色素瘤。

?

适用疾病: Mucosal Melanoma of the Head and Neck；Unresectable Mucosal Melanoma；Metastatic Mucosal Melanoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05101070 / NCI-2022-06439

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究S-531011单药及联合免疫检查点抑制剂用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Shionogi

正在招募 Phase 2

NCI NCT05546827 / NCI-2022-07760

Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma

AI 简述一项II期试验，研究免疫治疗联合放疗用于手术前的窦鼻和肛直肠黑色素瘤。

?

适用疾病: Stage 0 Anal Cancer；Stage I Anal Cancer；Stage II Anal Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05533697 / NCI-2022-07826

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究mRNA-4359单用或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: ModernaTX, Inc.

正在招募 Phase 2

NCI NCT05524935 / NCI-2022-08483

Olaparib in Combination with Pembrolizumab for the Treatment of Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究奥拉帕利联合帕博利珠单抗用于转移性葡萄膜黑色素瘤。

?

适用疾病: Stage IV Choroidal and Ciliary Body Melanoma；Metastatic Uveal Melanoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04971499 / NCI-2022-10496

Dapansutrile and Pembrolizumab for the Treatment of Refractory or Recurrent Advanced Melanoma, DREAM Study

AI 简述这是一项I/II期试验，研究Dapansutrile和Pembrolizumab用于晚期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Refractory Melanoma
干预: 未列出
地点: United States
申办方: Duke University Medical Center

正在招募 Phase 1, Phase 2

NCI NCT05200559 / NCI-2023-00563

E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer

AI 简述这是一项I/II期试验，研究E7777联合帕博利珠单抗用于复发或转移性实体瘤。在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2

NCI NCT05704647 / NCI-2023-00571

Nivolumab in Combination with Relatlimab in Treating Patients with Active Melanoma Brain Metastases

AI 简述这是一项II期试验，研究Nivolumab联合Relatlimab用于活动性黑色素瘤脑转移。

?

适用疾病: Stage IV Cutaneous (Skin) Melanoma；Metastatic Malignant Neoplasm in the Brain；Metastatic Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05094804 / NCI-2023-00782

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

AI 简述这是一项I/II期试验，研究OR2805单药及联合抗癌药用于转移性肉瘤、癌和黑色素瘤，在美国开展。

?

适用疾病: Metastatic Sarcoma；Metastatic Carcinoma；Metastatic Melanoma
干预: 未列出
地点: United States
申办方: OncoResponse Inc

正在招募 Phase 1, Phase 2

NCI NCT05584670 / NCI-2023-00867

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，首次人体研究SAR445877用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sanofi Aventis

正在招募 Phase 2

NCI NCT05077280 / NCI-2023-01823

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究立体定向体部放疗联合Opdualag用于转移性葡萄膜黑色素瘤。

?

适用疾病: Stage IV Choroidal and Ciliary Body Melanoma；Metastatic Uveal Melanoma
干预: 未列出
地点: United States
申办方: California Pacific Medical Center-Pacific Campus

正在招募 Phase 2

NCI NCT05503797 / NCI-2023-03273

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

AI 简述这是一项II期试验，研究FORE8394用于BRAF突变的晚期实体瘤。

?

适用疾病: Primary Central Nervous System Neoplasm；Metastatic Malignant Solid Tumor；Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Fore Biotherapeutics

正在招募 Phase 1, Phase 2

NCI NCT05786924 / NCI-2023-03966

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

AI 简述这是一项I/II期试验，研究S241656用于RAS/MAPK突变阳性恶性肿瘤。在美、丹、港、日等地开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Institut de Recherches Internationales Servier

正在招募 Phase 2

NCI NCT05839912 / NCI-2023-04467

Lymph Node Excision for Patients with Stage III Melanoma with One Clinically Positive Node, EXCILYNT Trial

AI 简述这是一项II期试验，研究淋巴结切除用于III期黑色素瘤伴一个临床阳性淋巴结。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Metastatic Melanoma
干预: 未列出
地点: United States
申办方: University of Virginia Cancer Center

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05669430 / NCI-2023-06313

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

AI 简述这是一项I/II期试验，研究GV20-0251单药或联合Pembrolizumab用于多种晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colon Cancer
干预: 未列出
地点: United States
申办方: GV20 Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06194929 / NCI-2023-09548

Defactinib and Avutometinib with or without Encorafenib for the Treatment of Patients with Brain Metastases from Cutaneous Melanoma

AI 简述这是一项I/II期试验，研究Defactinib和Avutometinib联合或不联合Encorafenib用于黑色素瘤脑转移。

?

适用疾病: Stage IV Cutaneous (Skin) Melanoma；Metastatic Cutaneous Melanoma；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 1, Phase 2

NCI NCT04752826 / NCI-2023-10441

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

AI 简述这是一项1/2期试验，研究BI-1808单药或联合帕博利珠单抗用于晚期恶性肿瘤，包括卵巢癌、T细胞淋巴瘤等。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: BioInvent International AB

正在招募 Phase 1, Phase 2

NCI NCT05914116 / NCI-2024-01206

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/IIa期试验，在美国研究DB-1311/BNT324用于晚期/转移性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06249048 / NCI-2024-03569

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

AI 简述这是一项I/II期试验，研究STX-001瘤内注射单药或联合Pembrolizumab用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Strand Therapeutics Inc.

正在招募 Phase 2

NCI NCT06365619 / NCI-2024-05648

Ipilimumab and Nivolumab before Surgery for the Treatment of Recurrent, High Risk, Resectable Stage IIIB-IV Metastatic Melanoma (NeoRelapse)

AI 简述这是一项II期试验，研究Ipilimumab和Nivolumab术前治疗用于复发高危可切除IIIB-IV期黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage IIIB Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 1, Phase 2

NCI NCT06598371 / NCI-2024-07763

Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究基因工程肿瘤浸润淋巴细胞KSQ-004EX用于多种晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06594991 / NCI-2024-07955

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People with Melanoma

AI 简述这是一项II期试验，研究Fianlimab、Cemiplimab和Ipilimumab联合用于黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Unresectable Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT06649058 / NCI-2024-08780

Consolidative Stereotactic Radiosurgery for the Treatment of Brain Metastases in Melanoma and Solid Tumor Cancer Patients, EXCLAIM Trial

AI 简述这是一项II期试验，研究立体定向放射外科治疗用于黑色素瘤和实体瘤脑转移。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Malignant Neoplasm in the Brain；Metastatic Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT07155317 / NCI-2025-03025

Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial

AI 简述这是一项II期试验，研究Ipilimumab和Nivolumab用于不可切除的IV期黑色素瘤。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Unresectable Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Emory University Hospital/Winship Cancer Institute

正在招募 Phase 2

NCI NCT06961006 / NCI-2025-03879

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

AI 简述这是一项II期试验，研究V940联合帕博利珠单抗用于III/IV期或不可切除的皮肤黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Unresectable Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1, Phase 2

NCI NCT06956690 / NCI-2025-04298

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚研究ENV-501用于HER3表达实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Hummingbird Bioscience

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT07070232 / NCI-2025-06009

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

AI 简述这是一项I/II期试验，研究BNT326联合BNT327用于晚期恶性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 2

NCI NCT06712927 / NCI-2025-09171

Relatlimab, Nivolumab, and Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma with Asymptomatic or Symptomatic Brain Metastases

AI 简述这是一项II期试验，研究Relatlimab、Nivolumab和Ipilimumab用于不可切除或转移性黑色素瘤伴脑转移。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Unresectable Melanoma
干预: 未列出
地点: United States
申办方: Stanford Cancer Institute Palo Alto

正在招募 Phase 1, Phase 2

NCI NCT07287917 / NCI-2026-00497

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究AMXT 1501和DFMO联合标准疗法用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Aminex Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT07288112 / NCI-2026-02580

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

AI 简述这是一项I/II期试验，研究DOC1021树突细胞免疫疗法用于难治性黑色素瘤。

?

适用疾病: Refractory Melanoma；Unresectable Melanoma；Metastatic Melanoma
干预: 未列出
地点: United States
申办方: Diakonos Oncology Corporation

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT02621021 / NCI-2018-02793

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合帕博利珠单抗用于转移性黑色素瘤，在美国开展。

?

适用疾病: Melanoma；Stage IV Cutaneous (Skin) Melanoma；Metastatic Malignant Neoplasm in the Brain
干预: young TIL，Pembrolizumab，Aldesleukin，Fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT02830724 / NCI-2018-03328

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

AI 简述这是一项I/II期试验，在美国开展，研究Anti-hCD70 CAR转导淋巴细胞用于表达CD70的胰腺癌、肾癌、乳腺癌、黑色素瘤、卵巢癌。

?

适用疾病: Pancreatic Cancer；Renal Cell Cancer；Breast Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Anti-hCD70 CAR transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物其他放疗

ClinicalTrials.gov NCT03340129

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

AI 简述一项II期试验，研究Ipilimumab联合Nivolumab和立体定向放疗用于IV期黑色素瘤。

?

适用疾病: Melanoma Stage Iv
干预: Ipilimumab，Nivolumab，Stereotactic Radiotherapy，Salvage therapy
地点: Australia，Norway
申办方: Melanoma Institute Australia

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03563729

Melanoma Metastasized to the Brain and Steroids

AI 简述这是一项II期试验，在丹麦开展，研究多种药物治疗恶性黑色素瘤脑转移。

?

适用疾病: Malignant Melanoma
干预: Pembrolizumab Injection [Keytruda]，Ipilimumab Injection [Yervoy]，Nivolumab Injection [Opdivo]，Encorafenib
地点: Denmark
申办方: Inge Marie Svane

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT03646617

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

AI 简述这是一项II期试验，研究ipilimumab联合nivolumab加或不加大分割放疗用于转移性黑色素瘤。

?

适用疾病: Metastatic Melanoma
干预: Hypofractionated Radiation Therapy (HFRT)，Nivolumab，Ipilimumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT03685890

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

AI 简述这是一项I/II期试验，研究纳武利尤单抗联合孤立肢体灌注用于黑色素瘤移行转移。

?

适用疾病: Melanoma；In-Transit Metastasis
干预: Nivolumab，Isolated limb perfusion (ILP)
地点: Netherlands，Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

AI 简述这是一项II期试验，研究Atezolizumab联合BDB001和放疗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Pancreatic Cancer；Virus-associated Tumors
干预: Association atezolizumab + BDB001 + RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001 + RT
地点: France
申办方: Institut Bergonié

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03947385 / NCI-2019-04523

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

AI 简述这是一项I/II期试验，研究IDE196用于GNAQ/11突变或PRKC融合的实体瘤，在美国、澳大利亚、加拿大开展。

?

适用疾病: Metastatic Uveal Melanoma；Cutaneous Melanoma；Colorectal Cancer
干预: IDE196，Binimetinib，Crizotinib
地点: United States，Australia，Canada
申办方: IDEAYA Biosciences

正在招募 Phase 1, Phase 2 生物制剂联合产品

ClinicalTrials.gov / NCI NCT04370587 / NCI-2020-11850

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究T3011单药及联合帕博利珠单抗用于晚期实体瘤，在美国和澳大利亚开展。

?

适用疾病: Solid Tumor；Melanoma；HNSCC
干预: T3011，T3011 + pembrolizumab
地点: United States，Australia
申办方: ImmVira Pharma Co. Ltd

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT04511013

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

AI 简述这是一项II期试验，比较Encorafenib+Binimetinib+Nivolumab与Ipilimumab+Nivolumab用于BRAF V600突变黑色素瘤脑转移。

?

适用疾病: Acral Lentiginous Melanoma；Clinical Stage IV Cutaneous Melanoma AJCC v8；Metastatic Cutaneous Melanoma
干预: Binimetinib，Encorafenib，Ipilimumab，Nivolumab
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04562129 / NCI-2020-07560

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

AI 简述这是一项II期试验，研究IL-2联合Ipilimumab后接Nivolumab用于III/IV期黑色素瘤。

?

适用疾病: Melanoma Stage III；Melanoma Stage IV；Inoperable Disease
干预: Interleukin-2，Ipilimumab，Nivolumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04598009

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

AI 简述这是一项II期试验，研究Binimetinib联合Imatinib用于不可切除III-IV期KIT突变黑色素瘤。

?

适用疾病: Melanoma Stage III；Melanoma Stage IV
干预: Binimetinib，Imatinib
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT04729543

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

AI 简述这是一项I/II期试验，研究MAGE-C2 TCR T细胞用于黑色素瘤和头颈癌。

?

适用疾病: Melanoma；Melanoma, Uveal；Head and Neck Cancer
干预: Adoptive therapy with autologous MC2 TCR T cells
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04771520 / NCI-2021-00702

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

AI 简述这是一项II期试验，研究Avapritinib用于CKIT或PDGFRA突变阳性晚期实体瘤。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Avapritinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05136196 / NCI-2021-12653

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

AI 简述这是一项II期试验，研究卡博替尼联合纳武利尤单抗用于晚期黑色素瘤或头颈鳞癌，在美国开展。

?

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Cabozantinib S-malate，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05155033 / NCI-2021-13967

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

AI 简述这是一项II期试验，研究PD-1抑制剂联合阿地白介素用于转移性黑色素瘤和肾细胞癌。

?

适用疾病: Metastatic Melanoma；Advanced Locoregional Melanoma；Metastatic Renal Cell Carcinoma
干预: Pembrolizumab，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05267626 / NCI-2023-07955

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

AI 简述这是一项I/II期试验，研究AU-007单药或联合用于不可切除局部晚期或转移性实体瘤。

?

适用疾病: Advanced Solid Tumor；Metastatic Cancer；Cutaneous Melanoma
干预: AU-007，Aldesleukin，Avelumab，Nivolumab
地点: United States，Australia
申办方: Aulos Bioscience, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05269381 / NCI-2022-01258

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究新抗原肽疫苗联合Pembrolizumab用于晚期实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIB Breast Cancer AJCC v8
干预: Cyclophosphamide，Neoantigen Peptide Vaccine，Pembrolizumab，Sargramostim
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT05296564

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

AI 简述这是一项I/II期试验，研究HBI 0201-ESO TCRT联合环磷酰胺和氟达拉滨用于NY-ESO-1阳性转移性癌症，在以色列开展。

?

适用疾病: Sarcoma, Synovial；Sarcoma,Soft Tissue；Melanoma Stage IV
干预: CYCLOPHOSPHAMIDE and FLUDARABIN，Cyclophosphamide，HBI 0201-ESO TCRT，Aldesleukin
地点: Israel
申办方: Hadassah Medical Organization

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05361174 / NCI-2022-07362

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

AI 简述这是一项I/II期试验，研究IOV-4001用于不可切除或转移性黑色素瘤或III/IV期非小细胞肺癌。

?

适用疾病: Unresectable Melanoma；Metastatic Melanoma；Stage III Non-small Cell Lung Cancer
干预: IOV-4001
地点: United States
申办方: Iovance Biotherapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05428007 / NCI-2022-08057

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

AI 简述这是一项II期试验，研究Sarilumab联合Ipilimumab、Nivolumab、Relatlimab用于不可切除的III或IV期黑色素瘤。

?

适用疾病: Melanoma；Unresectable Melanoma；Mucosal Melanoma
干预: Sarilumab，Ipilimumab Injection，Nivolumab/Relatlimab
地点: United States
申办方: NYU Langone Health

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05588453 / NCI-2021-14033

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

AI 简述这是一项I/II期试验，研究自然杀伤细胞疗法联合替莫唑胺用于IV期黑色素瘤脑转移。

?

适用疾病: Clinical Stage IV Cutaneous Melanoma AJCC v8；Metastatic Malignant Neoplasm in the Brain；Metastatic Melanoma
干预: Natural Killer Cell Therapy，Temozolomide
地点: United States
申办方: Kari Kendra

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05655312 / NCI-2023-02148

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

AI 简述这是一项I/II期试验，MC1R靶向α粒子单药及联合纳武利单抗用于晚期黑色素瘤。

?

适用疾病: Recurrent Melanoma (Skin)；Metastatic Melanoma；Melanoma Stage IV
干预: [203Pb]VMT01，[212Pb]VMT01，Nivolumab
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05779423 / NCI-2023-02847

Cryoablation+Ipilimumab+Nivolumab in Melanoma

AI 简述这是一项II期试验，研究冷冻消融联合Ipilimumab和Nivolumab用于晚期黑色素瘤。在美国等地开展。

?

适用疾病: Metastatic Melanoma；Skin Cancer；Unresectable Melanoma
干预: Ipilimumab，Nivolumab，Cryoablation
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

AI 简述这是一项I/II期试验，研究GI-102单药或联合其他药物用于晚期实体瘤。在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预: GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05877430 / NCI-2024-01737

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

AI 简述这是一项I/II期试验，研究CJRB-101联合Pembrolizumab用于晚期或转移性实体瘤，包括非小细胞肺癌、头颈癌等。

?

适用疾病: NSCLC；HNSCC；Melanoma
干预: CJRB-101，Pembrolizumab injection
地点: United States，South Korea
申办方: CJ Bioscience, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05896839 / NCI-2023-04306

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

AI 简述这是一项I/II期试验，研究免疫治疗联合泼尼松和西罗莫司用于肾移植受者皮肤癌。

?

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Ipilimumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05909618

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

AI 简述这是一项II期试验，在以色列研究Crizanlizumab单用或联合Nivolumab用于胶质母细胞瘤及脑转移黑色素瘤。

?

适用疾病: Advanced Glioblastoma；Metastatic Melanoma in the Central Nervous System；MGMT-Unmethylated Glioblastoma
干预: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]，Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
地点: Israel
申办方: Sheba Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05913388

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

AI 简述这是一项II期试验，在美国研究GB1211联合Pembrolizumab对比Pembrolizumab用于转移性黑色素瘤和头颈鳞癌。

?

适用疾病: Metastatic Melanoma；Head and Neck Squamous Cell Carcinoma
干预: GB1211，Pembrolizumab，Placebo
地点: United States
申办方: Providence Health & Services

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05970497 / NCI-2024-00730

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究KB707用于治疗局部晚期或转移性实体瘤。

?

适用疾病: Cancer；Melanoma Stage III；Melanoma Stage IV
干预: KB707，Opdualag，KEYTRUDA ®( Pembrolizumab)
地点: United States
申办方: Krystal Biotech, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06047379 / NCI-2024-08760

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

AI 简述这是一项1/2期试验，研究NEO212用于星形细胞瘤、胶质母细胞瘤或脑转移瘤。在美国开展。

?

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06060613 / NCI-2024-02051

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究OBX-115用于晚期实体瘤，在美国和澳大利亚等地开展。

?

适用疾病: Tumor Skin；Metastatic Melanoma；Melanoma
干预: OBX-115
地点: United States，Australia
申办方: Obsidian Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06070012 / NCI-2025-07100

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究Tebentafusp用于HLA-A*0201阳性未治疗转移性葡萄膜黑色素瘤。

?

适用疾病: Uveal Melanoma；Metastatic Uveal Melanoma
干预: Tebentafusp
地点: United States
申办方: Diwakar Davar

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06090266 / NCI-2024-10204

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

AI 简述这是一项I/II期试验，研究OR502单药及联合抗癌药用于晚期实体瘤。

?

适用疾病: Cancer；Tumor, Solid；Malignant Neoplasm
干预: OR502，Cemiplimab
地点: United States
申办方: OncoResponse, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06121180 / NCI-2023-09609

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究Cemiplimab联合Ziv-Aflibercept用于转移性葡萄膜黑色素瘤。

?

适用疾病: Metastatic Uveal Melanoma；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: ZIV-Aflibercept，Cemiplimab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06265025

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究GM103瘤内注射用于多种晚期实体瘤。

?

适用疾病: Head and Neck Cancer；Malignant Melanoma；Colorectal Cancer
干预: GM103 (Part A)，GM103 (Part B)，GM103 and Pembrolizumab (Part C)
地点: South Korea
申办方: GeneMedicine Co., Ltd.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06284590 / NCI-2024-08754

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

AI 简述这是一项II期试验，研究瘤内注射L19IL2或L19TNF或联合Pembrolizumab用于不可切除黑色素瘤。

?

适用疾病: Melanoma Stage III；Melanoma Stage IV；Stage III Cutaneous (Skin) Melanoma
干预: L19IL2，L19TNF，L19IL2/L19TNF，KEYTRUDA®
地点: United States
申办方: Philogen S.p.A.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06295159 / NCI-2024-02312

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

AI 简述这是一项II期试验，研究纳武利尤单抗单药或联合Relatlimab或伊匹木单抗用于局晚期黑色素瘤的新辅助和辅助治疗。

?

适用疾病: Melanoma Stage III；Melanoma Stage IV；Advanced Melanoma
干预: Nivolumab，Nivolumab + Relatlimab，Ipilimumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06319196

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

AI 简述这是一项II期试验，研究Opdualag和Nivolumab清除高危黑色素瘤分子残留病灶，在加拿大开展。

?

适用疾病: Cutaneous Melanoma；Melanoma Stage IV；Mucosal Melanoma
干预: Opdualag，Nivolumab
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06362369 / NCI-2024-03436

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

AI 简述这是一项I/II期试验，研究Alintegimod联合Ipilimumab及Nivolumab用于晚期实体瘤。

?

适用疾病: Advanced Cancer；Advanced Solid Tumor；Melanoma
干预: Alintegimod，Ipilimumab，Nivolumab
地点: United States
申办方: 7 Hills Pharma, LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06413680 / NCI-2024-06999

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

AI 简述这是一项I/II期试验，研究REGN10597联合Cemiplimab用于晚期实体瘤，包括黑素瘤和肾癌，在美国开展。

?

适用疾病: Melanoma；Clear-Cell Renal-Cell Carcinoma (ccRCC)；Advanced Solid Tumors
干预: REGN10597，Cemiplimab
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06414590 / NCI-2024-02357

Neoadjuvant Tebentafusp for Uveal Melanoma

AI 简述这是一项II期试验，研究Tebentafusp用于新辅助治疗局部晚期不可切除葡萄膜黑色素瘤，在美国开展。

?

适用疾病: Locally Advanced Unresectable Uveal Melanoma；Stage IIB Choroidal and Ciliary Body Melanoma；Stage III Choroidal and Ciliary Body Melanoma
干预: Tebentafusp-Tebn
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06425926 / NCI-2024-05762

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究GIM-531单独或联合抗PD-1抗体用于晚期实体瘤。

?

适用疾病: Melanoma Stage IV；Solid Tumor；Metastatic Malignant Solid Tumor
干预: GIM-531，Anti-PD-1 monoclonal antibody
地点: United States
申办方: Georgiamune Inc

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06626516 / NCI-2024-07367

Tebentafusp-tebn With LDT in Metastatic UM

AI 简述这是一项I/II期试验，研究Tebentafusp-tebn联合其他药物用于转移性葡萄膜黑色素瘤。

?

适用疾病: Metastatic Uveal Melanoma；Stage IV Choroidal and Ciliary Body Melanoma；Metastatic Malignant Neoplasm to the Liver
干预: Tebentafusp-Tebn，GM-CSF (Sargramostim)，BCNU
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06627244 / NCI-2025-00070

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究Tebentafusp联合放射栓塞用于转移性葡萄膜黑色素瘤。

?

适用疾病: Metastatic Uveal Melanoma；Metastatic Uveal Melanoma in the Liver；Stage IV Choroidal and Ciliary Body Melanoma
干预: Tebentafusp，TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
地点: United States
申办方: University of Miami

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06767306

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

AI 简述这是一项II期试验，在澳大利亚和加拿大研究立体定向消融放疗联合免疫治疗用于寡转移黑色素瘤。

?

适用疾病: Melanoma Metastatic
干预: Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy，Immunotherapy alone
地点: Australia，Canada
申办方: Melanoma Institute Australia

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06771544

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

AI 简述这是一项II期试验，研究Pembrolizumab联合环磷酰胺节拍化疗用于免疫检查点抑制剂难治性黑色素瘤。

?

适用疾病: Melanoma；Melanoma Stage III；Melanoma (Skin)
干预: Pembrolizumab，Cyclophosphamide
地点: United States
申办方: University of California, Irvine

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06932757 / NCI-2025-03538

Adjuvant Quisinostat in High-Risk Uveal Melanoma

AI 简述这是一项II期试验，研究Quisinostat用于高风险葡萄膜黑色素瘤的辅助治疗，在美国开展。

?

适用疾病: Uveal Melanoma；Uveal Class 2 Melanoma；Localized Uveal Melanoma
干预: Quisinostat
地点: United States
申办方: University of Miami

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06961357 / NCI-2025-05811

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

AI 简述这是一项I/II期试验，研究CD40L增强的TIL用于晚期黑色素瘤，在美国开展。

?

适用疾病: Melanoma；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: Cyclophosphamide，Fludarabine，Interleukin-2，TIL Product
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07057596

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究Tebentafusp用于转移性葡萄膜黑色素瘤，在德国、西班牙等地开展。

?

适用疾病: Mestastatic Uveal Melanoma
干预: Tebentafusp
地点: Germany，Spain
申办方: Grupo Español Multidisciplinar de Melanoma

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07063875

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

AI 简述这是一项I/II期试验，研究Aldesleukin联合Tebentafusp用于转移性葡萄膜黑色素瘤，在澳大利亚开展。

?

适用疾病: Uveal Melanoma；Metastatic Uveal Melanoma；Metastatic Uveal Melanoma in the Liver
干预: Aldesleukin
地点: Australia
申办方: St Vincent's Hospital, Sydney

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07115043 / NCI-2025-09704

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究AZD6750联合rilvegostomig用于多种晚期实体瘤。在美国、澳大利亚、日本、韩国等地开展。

?

适用疾病: Melanoma；Non-small Cell Lung Cancer；Squamous Cell Carcinoma (Skin)
干预: AZD6750，rilvegostomig
地点: United States，Australia，Japan，South Korea
申办方: AstraZeneca

正在招募 Phase 2 联合产品

ClinicalTrials.gov NCT07130032

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

AI 简述这是一项II期试验，在俄罗斯研究抗PD-1/PD-L1抗体联合贝伐珠单抗及低剂量环磷酰胺用于NSCLC和黑色素瘤。

?

适用疾病: Metastatic Non-small Cell Lung Cancer (NSCLC)；Metastatic Cutaneous Melanoma
干预: reICB regimen (NSCLC)，reICB regimen (melanoma)
地点: Russia
申办方: EuroCityClinic LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07136181 / NCI-2025-08783

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

AI 简述这是一项I/II期试验，研究NBM-BMX用于转移性葡萄膜黑色素瘤。在美国开展。

?

适用疾病: Metastatic Uveal Melanoma；Uveal Melanoma, Metastatic；Uveal Melanoma, Recurrent
干预: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
地点: United States
申办方: Novelwise Pharmaceutical Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07237100

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

AI 简述这是一项II期试验，研究Mirdametinib用于晚期NF1突变黑色素瘤。

?

适用疾病: Advanced Unresectable Melanoma；Metastatic Melanoma
干预: Mirdametinib
地点: United States
申办方: Kevin Kim, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07276386 / NCI-2025-09211

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

AI 简述这是一项II期试验，研究Melphalan/HDS经肝灌注联合Tebentafusp用于转移性葡萄膜黑色素瘤，在美国开展。

?

适用疾病: Metastatic Uveal Melanoma；Metastatic Malignant Neoplasm to the Liver
干预: Melphalan/HDS (Percutaneous Hepatic Perfusion)，Tebentafusp
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 器械药物

ClinicalTrials.gov / NCI NCT07281924 / NCI-2025-09113

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

AI 简述这是一项I/II期试验，研究Hepzato Kit和Opdualag（纳武利尤单抗+瑞拉利单抗）用于转移性黑色素瘤伴肝转移，在美国开展。

?

适用疾病: Metastatic Melanoma；Liver Metastases；Metastatic Malignant Neoplasm to the Liver
干预: Nivolumab and Relatlimab，Melphalan
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07339176

Intratumoral N17350 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究瘤内注射N17350用于晚期实体瘤。

?

适用疾病: Neoplasms, Solid Tumor；Breast Neoplasms, Triple-Negative；Squamous Cell Carcinoma of Skin
干预: N17350
地点: Australia
申办方: Onchilles Pharma Inc

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov / NCI NCT07405086 / NCI-2026-00433

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

AI 简述这是一项IV期试验，研究上午与下午给药免疫治疗用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Hepatocellular Carcinoma
干预: Biospecimen Collection，Immune Checkpoint Inhibitor
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07448831

A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

AI 简述这是一项2期试验，研究新辅助Pembrolizumab用于pT3b-T4a/b cN0M0黑色素瘤，在比利时开展。

?

适用疾病: Melanoma (Skin Cancer)
干预: Pembrolizumab
地点: Belgium
申办方: Universitair Ziekenhuis Brussel

正在招募 Phase 2 联合产品药物

ClinicalTrials.gov NCT07449754

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

AI 简述这是一项2期试验，研究Belvarafenib联合Cobimetinib用于NRAS突变晚期或转移性黑色素瘤，在韩国开展。

?

适用疾病: Advanced or Metastatic Melanoma
干预: Belvarafenib，Cobimetinib
地点: South Korea
申办方: Hanmi Pharmaceutical Company Limited

正在招募 Phase 4 器械药物

ClinicalTrials.gov / NCI NCT07504796 / NCI-2026-02907

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

AI 简述这是一项IV期试验，在Nivolumab和Relatlimab基础上，基于ctDNA指导加用Ipilimumab用于晚期黑色素瘤，在美国开展。

?

适用疾病: Metastatic Melanoma；Advanced Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: Nivolumab，Relatlimab，Ipilimumab，Signatera genome MRD assay
地点: United States
申办方: NYU Langone Health

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07440290

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

AI 简述这是一项II/III期试验，研究Dabrafenib联合Trametinib用于BRAF V600突变阳性癌症。在英国开展。

?

适用疾病: Haematological Malignancy；Malignant Neoplasm；Lymphoproliferative Disorders
干预: Dabrafenib，Trametinib
地点: United Kingdom
申办方: Cancer Research UK

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06683755 / NCI-2024-09421

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

AI 简述这是一项I/II期试验，研究Relatlimab、Ipilimumab和Nivolumab三联方案用于一线治疗不可切除或转移性黑色素瘤。

?

适用疾病: Melanoma；Unresectable Melanoma；Metastatic Melanoma
干预: Nivolumab，Relatlimab，Ipilimumab
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06708455

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

AI 简述这是一项II期试验，在美国开展，研究RAPA-201细胞治疗用于PD-(L)-1经治的转移性黑色素瘤。

?

适用疾病: Malignant Melanoma With Metastasis；Malignant Melanoma；Malignant Melanoma Stage IIIc
干预: RAPA-201 Rapamycin Resistant T Cells，Chemotherapy Prior to RAPA-201 Therapy
地点: United States
申办方: Rapa Therapeutics LLC

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07340619

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

AI 简述这是一项2期试验，研究prifetrastat联合fulvestrant用于转移性黑色素瘤。在法国开展。

?

适用疾病: Metastatic (Stage IV) Melanoma
干预: prifetrastat monotherapy for 15 days then combination with fulvestrant，prifetrastat in combination with fulvestrant
地点: France
申办方: UNICANCER

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07459543

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

AI 简述这是一项IV期试验，研究纳武利尤单抗+瑞拉利单抗固定剂量组合用于未经治疗的不可切除或转移性黑色素瘤。在印度开展。

?

适用疾病: Untreated Melanoma；Unresectable Melanoma；Metastatic Melanoma
干预: Nivolumab + Relatlimab
地点: India
申办方: Bristol-Myers Squibb

即将招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov NCT07576725

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

AI 简述这是一项II期试验，在乌干达研究低剂量减少频率的Nivolumab用于不可切除或转移性癌症。

?

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Nivolumab
地点: Uganda
申办方: Fred Hutchinson Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07631325

Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma

AI 简述这是一项I/II期试验，在美国研究Axelopran联合Nivolumab用于抗PD-1难治性黑色素瘤。

?

适用疾病: Unresectable Cutaneous Melanoma
干预: Axelopran，Nivolumab
地点: United States
申办方: John Kirkwood

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07636785

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

AI 简述这是一项I/II期试验，研究VMD-102用于肝细胞癌和其他实体瘤，在美国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Metastatic Uveal Melanoma；Renal Cell Carcinoma (RCC)
干预: VMD-102
地点: United States
申办方: VM Discovery, Inc.

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07651618

A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma

AI 简述这是一项2期试验，研究肿瘤浸润淋巴细胞过继细胞治疗用于免疫检查点抑制剂耐药黑色素瘤。在澳大利亚开展。

?

适用疾病: Melanoma (Skin Cancer)；Melanoma Metastatic
干预: Tumour Infiltrating Lymphocytes Adoptive Cell Therapy，Cyclophosphamide + Fludarabine Lymphodepletive Conditioning，Aldesleukin
地点: Australia
申办方: East Metropolitan Health Service, Australia

正在招募 Phase 1

NCI NCT00701987 / NCI-2010-01853

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

AI 简述这是一项I期试验，研究ALS-357用于转移性皮肤黑色素瘤。

?

适用疾病: Recurrent Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Advanced Life Sciences

正在招募 Phase 1

NCI NCT03098160 / NCI-2017-00995

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

AI 简述这是一项I期试验，研究Evofosfamide联合Ipilimumab用于多种晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Head and Neck Squamous Cell Carcinoma
干预: 未列出
地点: United States
申办方: Threshold Pharmaceuticals

正在招募 Phase 1

NCI NCT03385486 / NCI-2019-02747

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

AI 简述这是一项I期试验，研究TBX-3400用于免疫检查点抑制剂耐药或难治的III/IV期黑色素瘤。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Taiga Biotechnologies, Inc.

正在招募 Phase 1

NCI NCT03986606 / NCI-2019-05462

A Study of PSB205 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PSB205用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

正在招募 Phase 1

NCI NCT04137900 / NCI-2020-00511

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

AI 简述这是一项I期试验，研究抗BTLA抗体单药或联合抗PD-1抗体用于晚期恶性肿瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: TopAlliance Biosciences

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 Phase 1

NCI NCT04485013 / NCI-2020-07730

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

AI 简述这是一项I期试验，研究TTX-080用于晚期实体瘤，包括头颈鳞癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tizona Therapeutics, Inc

正在招募 Phase 1

NCI NCT04282044 / NCI-2021-03252

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究CRX100单药或联合帕博利珠单抗用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: BioEclipse Therapeutics

正在招募 Phase 1

NCI NCT05039801 / NCI-2021-09063

IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors

AI 简述这是一项I期试验，研究IACS-6274联合或不联合Bevacizumab和Paclitaxel用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT04572451 / NCI-2021-13072

Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors

AI 简述这是一项I期试验，研究立体定向放疗联合Nivolumab和BMS986253用于晚期实体瘤多发性转移，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1

NCI NCT04136834 / NCI-2022-01098

A Phase I Open-label Study for Subjects With Advanced Malignancies

AI 简述这是一项I期试验，研究新药用于晚期恶性肿瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Athenex, Inc.

正在招募 Phase 1

NCI NCT05077137 / NCI-2022-01409

Tetanus Diphtheria Vaccine or Polio Boost Vaccine for Increasing Response to Immune Checkpoint Inhibitor Therapy in Patients with Advanced or Metastatic Melanoma

AI 简述这是一项I期试验，研究破伤风白喉疫苗或脊髓灰质炎加强疫苗用于晚期黑色素瘤。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Duke University Medical Center

正在招募 Phase 1

NCI NCT05355701 / NCI-2022-06211

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

AI 简述这是一项I期试验，研究PF-07799933用于BRAF突变晚期实体瘤，在美国、加拿大、以色列等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Pfizer Inc

正在招募 Phase 1

NCI NCT05785754 / NCI-2023-05513

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DCSZ11单药及联合治疗用于晚期或转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DynamiCure Biotechnology

正在招募 Phase 1

NCI NCT06021626 / NCI-2023-06972

A Study of CRD3874-SI in People With Locally Advanced or Metastatic Malignant Solid Tumor

AI 简述这是一项I期试验，研究CRD3874-SI用于局部晚期或转移性恶性实体瘤。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT05848739 / NCI-2023-08892

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

AI 简述这是一项1-2期试验，研究ST316用于晚期不可切除和转移性实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Sapience Therapeutics

正在招募 Phase 1

NCI NCT06108050 / NCI-2024-01130

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究JZP898单药或联合Pembrolizumab用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 1

NCI NCT05264974 / NCI-2024-02118

RNA-Lipid Particle Vaccine for the Treatment of Early Melanoma Recurrence after Anti-PD-1 Antibody Therapy or Uresectable or Metastatic Soft Tissue Sarcoma

AI 简述这是一项I期试验，研究RNA脂质颗粒疫苗用于早期黑色素瘤复发或不可切除/转移性软组织肉瘤。

?

适用疾病: Metastatic Uveal Melanoma；Unresectable Soft Tissue Sarcoma；Metastatic Soft Tissue Sarcoma
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 1

NCI NCT06150664 / NCI-2024-04028

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

AI 简述这是一项I期试验，研究CTX-8371用于多种晚期恶性肿瘤。

?

适用疾病: Stage III Lip and Oral Cavity Cancer；Stage IV Lip and Oral Cavity Cancer；Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: Compass Therapeutics

正在招募 O

NCI NCT06472661 / NCI-2024-08789

Focused Ultrasound Ablation and Intratumoral PolyICLC for the Treatment of Patients with Advanced Resectable Melanoma Receiving Immunotherapy before Surgery

AI 简述这是一项其他类型试验，研究聚焦超声消融和瘤内PolyICLC用于可切除黑色素瘤。

?

适用疾病: Advanced Melanoma；Resectable Melanoma
干预: 未列出
地点: United States
申办方: University of Virginia Cancer Center

正在招募 Phase 1

NCI NCT06660420 / NCI-2024-08948

PRAME-TCR-NK Cells for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Recurrent and/or Refractory Melanoma, PRAMETIME-Mel Trial

AI 简述这是一项1期试验，研究PRAME-TCR-NK细胞用于局部晚期或转移性黑色素瘤，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Choroidal and Ciliary Body Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT07197671 / NCI-2025-08356

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer

AI 简述这是一项I期试验，研究Y-NM600联合免疫检查点抑制剂用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT07252479 / NCI-2026-00268

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

AI 简述这是一项I期试验，研究RAS抑制剂用于携带RAS突变的晚期或转移性实体瘤，于美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Adlai Nortye Biopharma Co., Ltd.

正在招募 Phase 1

NCI NCT07317505 / NCI-2026-01129

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究JMT108用于治疗晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Conjupro Bio-Pharmaceuticals Inc

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03454035 / NCI-2017-02445

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

AI 简述这是一项I期试验，研究Ulixertinib和Palbociclib用于晚期胰腺癌和其他实体瘤。

?

适用疾病: Tumor, Solid；Pancreatic Cancer；Melanoma
干预: Ulixertinib，Palbociclib
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 生物制剂药物其他

ClinicalTrials.gov / NCI NCT04119024 / NCI-2019-05764

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究基因修饰免疫细胞用于晚期黑色素瘤或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Neoplasm；Metastatic Melanoma；Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Anusha Kalbasi

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT04697576 / NCI-2020-13282

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

AI 简述这是一项I期试验，研究瘤内注射流感疫苗联合Ipilimumab、Nivolumab或Pembrolizumab用于I-IV期黑色素瘤。

?

适用疾病: Clinical Stage I Cutaneous Melanoma AJCC v8；Clinical Stage IA Cutaneous Melanoma AJCC v8；Clinical Stage IB Cutaneous Melanoma AJCC v8
干预: Ipilimumab，Nivolumab，Pembrolizumab，Quadrivalent Inactivated Influenza Vaccine
地点: United States
申办方: Carlo Contreras

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT04741997 / NCI-2021-01124

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

AI 简述这是一项早期1期试验，研究Encorafenib和Binimetinib联合Nivolumab用于黑色素瘤辅助治疗。

?

适用疾病: Melanoma Stage III；Melanoma Stage IV；BRAF V600 Mutation
干预: Encorafenib Pill，Binimetinib Pill，Nivolumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04793737

Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

AI 简述这是一项试验，在瑞典研究精准放疗用于免疫治疗耐药的转移性黑色素瘤。

?

适用疾病: Metastatic Melanoma
干预: Precision Radiation (SBRT)
地点: Sweden
申办方: Karolinska University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04855435

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

AI 简述这是一项I期试验，研究MBS8(1V270)单药或联合pembrolizumab用于晚期实体瘤，在丹麦、西班牙开展。

?

适用疾病: Advanced Solid Tumor；Uveal Melanoma, Metastatic；Cutaneous Melanoma
干预: MBS8(1V270)，MBS8(1V270) and pembrolizumab combination
地点: Denmark，Spain
申办方: MonTa Biosciences ApS

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04903119 / NCI-2021-01699

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

AI 简述这是一项I期试验，研究Nilotinib联合达拉非尼/曲美替尼或encorafenib/binimetinib用于BRAF突变转移性黑色素瘤。

?

适用疾病: Metastatic Melanoma；BRAF Gene Mutation；Unresectable Melanoma
干预: Nilotinib 100mg，Nilotinib 200mg，Nilotinib 300mg，Nilotinib 400mg
地点: United States
申办方: Rina Plattner

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05076760 / NCI-2022-02030

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

AI 简述这是一项I期试验，研究MEM-288溶瘤病毒单用或联合标准治疗用于晚期实体瘤。

?

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MEM-288 Intratumoral Injection，Nivolumab，Docetaxel
地点: United States
申办方: Memgen, Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05098210 / NCI-2021-10199

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究个体化新抗原肽疫苗联合纳武利尤单抗用于黑色素瘤、乳腺癌或非小细胞肺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8；Locally Advanced Cutaneous Melanoma
干预: Neoantigen Peptide Vaccine，Nivolumab，Poly ICLC，Echocardiography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT05498792 / NCI-2022-10371

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

AI 简述这是一项早期I期试验，研究CBL0137联合Ipilimumab和Nivolumab用于晚期黑色素瘤。

?

适用疾病: Locally Advanced or Metastatic Melanoma；Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma
干预: CBL0137，Ipilimumab，Nivolumab
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项1期试验，研究Enzelkitug单药或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05607095 / NCI-2022-09647

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

AI 简述这是一项I期试验，研究Lifileucel (LN-144/LN-145)用于晚期葡萄膜黑色素瘤或未分化多形性肉瘤。

?

适用疾病: Uveal Melanoma；Melanoma；Metastatic Uveal Melanoma
干预: Lifileucel (LN-144/LN-145)
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05629546 / NCI-2024-04954

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

AI 简述这是一项I期试验，研究记忆样自然杀伤细胞联合Nivolumab和Relatlimab用于晚期黑色素瘤。

?

适用疾病: Advanced Melanoma；Metastatic Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: Cytokine-induced memory-like natural killer cells，Relatilmab，Nivolumab
地点: United States
申办方: Washington University School of Medicine

正在招募阶段未标明药物

ClinicalTrials.gov NCT05652673

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

AI 简述这是一项在荷兰开展的试验，安全停用伊匹木单抗-纳武利单抗用于III/IV期黑色素瘤。

?

适用疾病: Melanoma Stage IV；Melanoma Stage III；Immunotherapy
干预: nivolumab
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05746897

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究NM1F（抗PVRIG）用于晚期实体瘤，包括卵巢癌、黑色素瘤等，在美国开展。

?

适用疾病: Ovarian Cancer；Melanoma；Triple Negative Breast Cancer
干预: NM1F Injection，Pembrolizumab injection
地点: United States
申办方: Hefei TG ImmunoPharma Co., Ltd.

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT05837767 / NCI-2023-06276

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

AI 简述这是一项临床试验，研究姑息放疗用于软组织转移的实体瘤。

?

适用疾病: Invasive Ductal Breast Carcinoma；Invasive Ductal Breast Carcinoma Stage IV；Lobular Breast Carcinoma
干预: Palliative radiotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05859074 / NCI-2023-04168

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

AI 简述这是一项I期试验，研究MQ719单用或联合Pembrolizumab用于晚期实体瘤，在美国开展。

?

适用疾病: Cutaneous Squamous Cell Carcinoma；SCC - Squamous Cell Carcinoma；Basal Cell Carcinoma
干预: MQ719，Pembrolizumab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募阶段未标明药物

ClinicalTrials.gov NCT05878977

Biomarkers in Immunotherapy of Melanoma

AI 简述这是一项标志物研究，分析免疫检查点抑制剂治疗转移性黑色素瘤的生物标志物，在斯洛文尼亚开展。

?

适用疾病: Metastatic Melanoma；Immune Checkpoints Inhibitors；Gastrointestinal Microbiome (Bacterial and Viral)
干预: Immune checkpoint inhibitor
地点: Slovenia
申办方: Institute of Oncology Ljubljana

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05968690

Naltrexone and Propranolol Combined With Immunotherapy

AI 简述这是一项I期试验，研究Naltrexone和Propranolol联合免疫治疗用于晚期黑色素瘤。

?

适用疾病: Advanced Melanoma
干预: Propranolol，Naltrexone
地点: United States
申办方: Sarah Weiss

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06022029

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

AI 简述这是一项I期试验，研究瘤内ONM-501单药或联合cemiplimab用于晚期实体瘤和淋巴瘤。

?

适用疾病: Triple Negative Breast Cancer；Diffuse Large B Cell Lymphoma；Follicular Lymphoma
干预: ONM-501，Cemiplimab
地点: United States，Australia
申办方: OncoNano Medicine, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06066138

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

AI 简述这是一项I期试验，研究基于治疗药物监测的Atezolizumab给药方案用于多种晚期肉瘤和肺癌。在美国开展。

?

适用疾病: Locally Advanced Alveolar Soft Part Sarcoma；Metastatic Alveolar Soft Part Sarcoma；Locally Advanced Non Small Cell Lung Cancer
干预: Atezolizumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT06204991

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

AI 简述这是一项I期试验，研究ADP-TILIL7用于局部晚期或转移性黑色素瘤。

?

适用疾病: Melanoma Stage III；Melanoma Stage IV；Melanoma
干预: ADP-TILIL7，Cyclophosphamide，Fludarabine Phosphate，Proleukin
地点: Denmark
申办方: Inge Marie Svane

正在招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT06216938

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

AI 简述这是一项早期I期试验，研究RP1用于原发性黑色素瘤以降低前哨淋巴结转移风险。

?

适用疾病: Melanoma
干预: Vusolimogene oderparepvec (RP1)
地点: United States
申办方: Yana Najjar

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT06305962

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

AI 简述这是一项早期I期试验，研究177Lu-抗PD-L1单域抗体用于转移性实体瘤。

?

适用疾病: PDL1 Gene Mutation；Non Small Cell Lung Cancer；Small Cell Lung Cancer ( SCLC )
干预: 177Lu-RAD204
地点: Australia
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06326411

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究NST-628口服片剂用于实体瘤，在美国和澳大利亚开展。

?

适用疾病: Oncology；MEK Mutation；RAF Gene Mutation
干预: NST-628
地点: United States，Australia
申办方: Nested Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06332755

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

AI 简述这是一项I期试验，研究LB-LR1109单药用于实体瘤及联合阿替利珠单抗用于非小细胞肺癌等多种癌症，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer(NSCLC)；Head and Neck Squamous Cell Carcinoma(HNSCC)；Renal Cell Carcinoma(RCC)
干预: Phase 1a: LB-LR1109，Phase 1b: LB-LR1109 and Atezolizumab
地点: United States
申办方: LG Chem

正在招募阶段未标明其他手术/操作

ClinicalTrials.gov NCT06363591

WoW - Single- vs Two-staged Excisions of Thin Melanoma

AI 简述这是一项试验，比较单次与两次切除用于薄层黑色素瘤，在瑞典开展。

?

适用疾病: Melanoma
干预: Surgery，No Surgery
地点: Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

AI 简述这是一项I期试验，研究VET3-TGI与Atezolizumab用于多种实体瘤。

?

适用疾病: Solid Tumor, Adult；Microsatellite Stable Colorectal Cancer；Head and Neck Squamous Cell Carcinoma
干预: VET3-TGI，Atezolizumab
地点: United States
申办方: KaliVir Immunotherapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06545682 / NCI-2024-06339

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

AI 简述这是一项I期试验，研究Alpelisib联合Pembrolizumab用于转移性乳腺癌或黑色素瘤。在美国等地开展。

?

适用疾病: Melanoma (Skin Cancer)；Breast Cancer；Brain Metastasases
干预: Alpelisib + Pembrolizumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06783270

T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

AI 简述这是一项I期试验，研究CRISPR编辑PD1的肿瘤浸润淋巴细胞治疗用于转移性黑色素瘤，在丹麦开展。

?

适用疾病: Melanoma Metastatic
干预: TIL therapy
地点: Denmark
申办方: Inge Marie Svane

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06805825 / NCI-2025-01427

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

AI 简述这是一项I期试验，研究c-Kit特异性抗体药物偶联物NN3201用于表达c-Kit的晚期实体瘤。

?

适用疾病: Gastrointestinal Stromal Tumors；Small-cell Lung Cancer；Adenoid Cystic Carcinoma
干预: NN3201
地点: United States
申办方: Novelty Nobility, Inc.

正在招募 Phase 1 生物制剂药物放疗

ClinicalTrials.gov NCT06889766

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

AI 简述这是一项I期试验，研究NY-ESO-1重定向T细胞用于晚期黑色素瘤和肉瘤，在瑞士开展。

?

适用疾病: Advanced Melanoma；Melanoma Metastatic；Sarcoma
干预: NY-ESO-1 TCR redirected autologous T cell product，Low-dose irradiation，Non-myeloablative lymphodepleting chemotherapy
地点: Switzerland
申办方: Centre Hospitalier Universitaire Vaudois

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06946225 / NCI-2025-06676

ACTengine® IMA203 Combined With mRNA-4203

AI 简述这是一项I期试验，研究IMA203联合mRNA-4203用于晚期皮肤黑色素瘤和滑膜肉瘤。

?

适用疾病: Cutaneous Melanoma；Synovial Sarcoma；Stage III Cutaneous (Skin) Melanoma
干预: IMA203，mRNA-4203
地点: United States
申办方: Immatics US, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07027488 / NCI-2025-06053

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究AB821用于晚期黑色素瘤、默克尔细胞癌等实体瘤。

?

适用疾病: Advanced Melanoma and Normal or Impaired；Advanced Melanoma；Recurrent Merkel Cell Cancer
干预: AB821
地点: United States
申办方: Yale University

正在招募 Phase 1 诊断检测药物

ClinicalTrials.gov NCT07076550

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

AI 简述这是一项I期试验，研究A9-3408用于转移性黑色素瘤。

?

适用疾病: Melanoma Metastatic；Uveal Melanoma, Metastatic；Mucosal Melanoma
干预: [225Ac]Ac-A9-3408，[68Ga]Ga-A9T-3202
地点: Australia
申办方: Alpha-9 Oncology USA Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07086105

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

AI 简述这是一项I期试验，在澳大利亚开展，研究Adze1.C用于转移性黑色素瘤。

?

适用疾病: Metastatic Melanoma
干预: Adze1.C
地点: Australia
申办方: Adze Biotechnology Australia Pty Ltd

正在招募阶段未标明放疗

ClinicalTrials.gov NCT07112170

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

AI 简述这是一项观察性试验，在加拿大开展，研究立体定向体部放疗(SBRT)用于转移性黑色素瘤。

?

适用疾病: Metastatic Melanoma；OligoProgressive Metastatic Disease
干预: Stereotactic Body Radiation Therapy (SBRT)
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07203391

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

AI 简述这是一项I期试验，研究Roginolisib用于转移性葡萄膜黑色素瘤，在澳大利亚开展。

?

适用疾病: Uveal Melanoma, Metastatic
干预: roginolisib
地点: Australia
申办方: St Vincent's Hospital, Sydney

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07237594

IL-17 Blockade to Decrease irAEs (REPLAY)

AI 简述这是一项I期试验，研究Secukinumab减轻免疫相关不良事件用于转移性黑色素瘤。

?

适用疾病: Metastatic Melanoma
干预: Secukinumab Injection
地点: United States
申办方: Duke University

正在招募阶段未标明药物

ClinicalTrials.gov NCT07407166

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

AI 简述这是一项观察性研究，评估一线免疫治疗用于斯洛文尼亚转移性黑色素瘤的疗效。

?

适用疾病: Metastatic Melanoma；Melanoma
干预: Immunotherapy
地点: Slovenia
申办方: Institute of Oncology Ljubljana

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07501117

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

AI 简述这是一项I期试验，研究纳武利尤单抗和伊匹木单抗新辅助治疗用于高危眼黑色素瘤。

?

适用疾病: Uveal Melanoma
干预: Nivolumab & Ipilimumab
地点: Denmark
申办方: Inge Marie Svane

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07584226 / NCI-2026-03770

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

AI 简述这是一项I期试验，研究RLY-8161用于晚期NRAS突变实体瘤（包括黑色素瘤）。在美国开展。

?

适用疾病: Advanced NRAS-Mutant Melanoma；Advanced NRAS-Mutant Solid Tumors；NRAS Mutation
干预: RLY-8161
地点: United States
申办方: Relay Therapeutics, Inc.

暂时不招募 Phase 2

NCI NCT00338377 / NCI-2012-01368

Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合或不联合树突状细胞用于转移性黑色素瘤。

?

适用疾病: Stage III Uveal Melanoma；Stage IV Uveal Melanoma；Recurrent Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT02910700 / NCI-2016-01940

Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

AI 简述这是一项II期试验，在美国开展，研究Nivolumab联合Trametinib和Dabrafenib或Encorafenib和Binimetinib用于BRAF突变转移性或不可切除III-IV期黑色素瘤。

?

适用疾病: Unresectable Melanoma；Metastatic Malignant Neoplasm in the Brain；Stage IIIA Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT03175432 / NCI-2018-01188

Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases

AI 简述这是一项II期试验，研究贝伐珠单抗和阿替利珠单抗联合或不联合考比替尼用于未经治疗的黑色素瘤脑转移。

?

适用疾病: Stage IV Cutaneous (Skin) Melanoma；Refractory Melanoma；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT03131908 / NCI-2018-01609

PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss

AI 简述这是一项I/II期试验，研究PI3K-beta抑制剂GSK2636771联合Pembrolizumab用于PTEN缺失的III-IV期癌症，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT03919292 / NCI-2019-02675

Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers

AI 简述这是一项I/II期试验，研究Neratinib和Divalproex Sodium用于晚期实体瘤或RAS突变癌症，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colon Cancer；Stage IV Colon Cancer
干预: 未列出
地点: United States
申办方: VCU Massey Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT03970382 / NCI-2019-03772

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究基因编辑的TCR T细胞联合或不联合抗PD-1用于多种实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: PACT Pharma, Inc.

暂时不招募 Phase 1

NCI NCT04418167 / NCI-2020-06750

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

AI 简述这是一项I期试验，研究JSI-1187-01单药或联合Dabrafenib用于MAPK通路突变的晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: JS InnoPharm, LLC

暂时不招募 Phase 1

NCI NCT04714983 / NCI-2021-00608

DNX-2440 for Resectable Colorectal Liver Metastasis

AI 简述这是一项I期试验，研究DNX-2440用于可切除的结直肠癌肝转移，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DNAtrix, Inc.

暂时不招募 Phase 2

NCI NCT04899908 / NCI-2021-09443

Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases

AI 简述这是一项II期试验，研究立体定向脑部放疗联合AGuIX钆基纳米颗粒用于脑转移瘤，来自肺癌、乳腺癌、黑色素瘤等。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Digestive System Cancer；Stage IV Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT06237881 / NCI-2024-00734

KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AI 简述这是一项1/2期试验，研究KSQ-001EX用于晚期黑色素瘤、复发非小细胞肺癌或复发头颈部鳞癌。

?

适用疾病: Recurrent Head and Neck Squamous Cell Cancer；Stage IV Cutaneous (Skin) Melanoma；Stage IIIC Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募阶段未标明

NCI NCT07655583 / NCI-2026-04559

Removing Radiation Therapy from the Treatment of Brain Metastases in Patients with Melanoma or Non-small Cell Lung Cancer who are Receiving CNS-Active Systemic Therapy after Resection, OBSERVE Trial

AI 简述这是一项观察性试验，探索在脑转移切除术后取消放疗，用于黑色素瘤或非小细胞肺癌。

?

适用疾病: Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07476326

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

AI 简述这是一项I期试验，比较Bmab1700与Opdivo辅助单药治疗黑色素瘤。

?

适用疾病: Melanoma
干预: Bmab1700，Opdivo
地点: Georgia，Romania，Serbia，South Africa 等 2 个
申办方: Biocon Biologics UK PLC

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05275374

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

AI 简述这是一项I/II期试验，研究XP-102单药或联合Trametinib用于BRAF V600突变晚期实体瘤。

?

适用疾病: Cancer；BRAF V600 Mutation；Melanoma
干预: XP-102，Trametinib
地点: 未列出
申办方: Xynomic Pharmaceuticals, Inc.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT05903937

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

AI 简述这是一项I期试验，研究局部注射自体肿瘤浸润淋巴细胞联合清淋治疗用于黑色素瘤肝转移。

?

适用疾病: Uveal Melanoma；Metastatic Cutaneous Melanoma
干预: Autologous Tumor Infiltrating Lymphocytes，Melphalan，Interleukin-2
地点: 未列出
申办方: Vastra Gotaland Region

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06327698

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

AI 简述这是一项II期试验，研究Cadonilimab联合安罗替尼用于一线治疗失败的局部进展或转移性黑色素瘤。

?

适用疾病: Melanoma
干预: Cadonilimab，anlotinib
地点: 未列出
申办方: Hunan Cancer Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07183852

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

AI 简述这是一项I期试验，研究肿瘤浸润淋巴细胞用于转移性黑色素瘤。

?

适用疾病: Metastatic Uveal Melanoma；Metastatic Cutaneous Melanoma
干预: Autologous Tumor Infiltrating Lymphocytes (TIL)，Melphalan，Interleukin-2
地点: 未列出
申办方: Vastra Gotaland Region

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07252661

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ACC-1898用于晚期实体瘤。

?

适用疾病: Hepatocellular Carcinoma；Renal Cell Carcinoma；Thyroid Carcinoma, Medullary
干预: ACC-1898
地点: 未列出
申办方: AccSalus Biosciences, Inc.

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07406724

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

AI 简述这是一项II期试验，研究HS-IT101注射与化疗比较用于晚期黑色素瘤。

?

适用疾病: Melanoma (Excluding Uveal Melanoma)
干预: Tumor Tissue Sampling，Lymphodepletion Conditioning，Infusion of HS-IT101 Injection，IL-2 Administration for Tumor-Infiltrating Lymphocyte (TIL) Therapy
地点: 未列出
申办方: Qingdao Sino-Cell Biomedicine Co., Ltd.

即将招募 Phase 2 器械药物

ClinicalTrials.gov NCT07619898

PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure

AI 简述这是一项II期试验，研究体外光化学疗法用于晚期黑色素瘤免疫相关结肠炎和肝炎对类固醇反应不佳的患者。

?

适用疾病: Colitis；Hepatitis；Melanoma (Skin Cancer)
干预: methoxsalen，Extracorporeal photopheresis (ECP)，Vedolizumab，Infliximab
地点: 未列出
申办方: Therakos LLC

术语	中文意思	对找临床试验有什么用
转移性黑色素瘤 / Metastatic melanoma	黑色素瘤已经扩散到远处器官或组织。	很多系统治疗或免疫治疗试验会限定 metastatic 患者。
BRAF V600	黑色素瘤中重要的可检测突变类型之一。	可以找 BRAF/MEK 抑制剂、联合免疫治疗相关试验。
NRAS mutation	另一类黑色素瘤相关突变。	可以找 MEK、免疫联合或 RAS pathway 相关试验。
KIT mutation	部分黏膜型或肢端型黑色素瘤可能出现 KIT 改变。	可以找 KIT inhibitor 或特定亚型试验。
PD-1 / CTLA-4	免疫检查点治疗相关靶点。	黑色素瘤海外试验常见免疫治疗、联合治疗或耐药后治疗方向。
Uveal melanoma	葡萄膜黑色素瘤，和皮肤黑色素瘤不同。	需要单独搜索 uveal melanoma，试验方向不同。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

黑色素瘤

当前同步到的治疗类试验